川芎嗪对慢性心力衰竭患者血清NT-proBNP水平影响的研究

目的探讨川芎嗪对慢性心力衰竭(CHF)患者氨基末端脑钠肽前体(NT-proBNP)水平的影响。方法将52例CHF患者随机分为治疗组27例和对照组25例。对照组仅予以常规治疗;治疗组在对照组治疗基础上加用川芎嗪治疗,疗程均为14d。2组治疗前、后分别采血检测并比较血清NT-proBNP水平。结果 2组治疗后NT-proBNP水平低于本组治疗前,且治疗组低于对照组,差异均有统计学意义(P<0.05和P<0.01)。结论 CHF患者血清NT-proBNP水平明显增高,在常规治疗基础上加用川芎嗪治疗可进一步降低心力衰竭患者血清NT-proBNP水平。

The influence from Ligustrazine on serum NT-proBNP level of patients with chronic heart failure

Objective To deserve the influence from Ligustrazine on serum NT-proBNP level of patients with chronic heart failure(CHF).Methods 52 cases of CHF were divided into the test group(n=27) and the control group(n=25) randomly.For the test group,Ligustrazine and conventional western medicine approach was put into practice.As for the control group,only conventional approach was carried out.The treatment lasted 14 days and serum NT-proBNP level was measured before and after the cure.Then the deviation of serum NT-proBNP level of two groups was analyzed respectively.Results NT-proBNP level of two groups descended remarkably,while NT-proBNP level of the test group descended even more(P<0.05 and P<0.01).Conclusion NT-proBNP level of patients with CHF is observably higher than the normal.And the implement of ligustrazine on the fundament of conventional cure could reduce NT-proBNP level of CHF more effectively.